05618nam 2200721 450 991081786870332120200520144314.03-527-67615-53-527-67613-93-527-67614-7(CKB)3710000000222912(EBL)1767041(SSID)ssj0001413784(PQKBManifestationID)11870829(PQKBTitleCode)TC0001413784(PQKBWorkID)11417735(PQKB)11606358(MiAaPQ)EBC1767041(MiAaPQ)EBC4044551(Au-PeEL)EBL1767041(CaPaEBR)ebr10909201(CaONFJC)MIL637255(OCoLC)888352788(PPN)189378581(EXLCZ)99371000000022291220140901h20152015 uy 0engur|n|---|||||txtccrNovel antimicrobial agents and strategies /edited by David A. Phoenix, Frederick Harris and Sarah R. Dennison ; contributors Waqar Ahmed [and thirty one others]Weinheim, Germany :Wiley-VCH,2015.©20151 online resource (439 p.)Description based upon print version of record.3-527-33638-9 Includes bibliographical references at the end of each chapters and index.Novel Antimicrobial Agents and Strategies; Contents; List of Contributors; Preface; Chapter 1 The Problem of Microbial Drug Resistance; 1.1 Introduction; 1.2 History of the Origins, Development, and Use of Conventional Antibiotics; 1.3 Problems of Antibiotic Resistance; 1.4 Multiple Drug-Resistant (MDR), Extensively Drug-Resistant (XDR), and Pan-Drug-Resistant (PDR) Organisms; 1.5 MDR Mechanisms of Major Pathogens; 1.6 Antimicrobial Stewardship Programs; 1.7 Discussion; Acknowledgment; References; Chapter 2 Conventional Antibiotics -- Revitalized by New Agents; 2.1 Introduction2.2 Conventional Antibiotics2.3 The Principles of Combination Antibiotic Therapy; 2.4 Antibiotic Resistance Breakers: Revitalize Conventional Antibiotics; 2.4.1 β-Lactamase Inhibitors; 2.4.2 Aminoglycoside-Modifying Enzyme Inhibitors; 2.4.3 Antibiotic Efflux Pumps Inhibitors; 2.4.4 Synergy Associated with Bacterial Membrane Permeators; 2.5 Discussion; Acknowledgments; References; Chapter 3 Developing Novel Bacterial Targets: Carbonic Anhydrases as Antibacterial Drug Targets; 3.1 Introduction; 3.2 Carbonic Anhydrases; 3.3 CA Inhibitors; 3.4 Classes of CAs Present in Bacteria3.5 Pathogenic Bacterial CAs3.6 α-CAs in Pathogenic Bacteria; 3.7 β-CAs in Pathogenic Bacteria; 3.8 γ-CAs from Pathogenic Bacteria; 3.9 Conclusions; References; Chapter 4 Magainins -- A Model for Development of Eukaryotic Antimicrobial Peptides (AMPs); 4.1 Introduction; 4.2 Magainins and Their Antimicrobial Action; 4.3 Magainins as Antibiotics; 4.4 Other Antimicrobial Uses of Magainins; 4.5 Future Prospects for Magainins; References; Chapter 5 Antimicrobial Peptides from Prokaryotes; 5.1 Introduction; 5.2 Bacteriocins; 5.2.1 Microcins -- Peptide Bacteriocins from Gram-Negative Bacteria5.2.2 Lanthibiotics -- Post-translationally Modified Peptides from Gram-Positive Bacteria5.2.3 Non-modified Peptides from Gram-Positive Bacteria; 5.3 Applications of Prokaryotic AMPs; 5.3.1 Food Biopreservation; 5.3.2 Bacteriocinogenic Probiotics; 5.3.3 Clinical Application; 5.3.4 Applications in Dental Care; 5.4 Development and Discovery of Novel AMP; References; Chapter 6 Peptidomimetics as Antimicrobial Agents; 6.1 Introduction; 6.2 Antimicrobial Peptidomimetics; 6.2.1 Peptoids; 6.2.2 β-Peptides; 6.2.3 Arylamides; 6.2.4 β-Peptoid--Peptide Hybrid Oligomers6.2.5 Oligourea and γ 4-Peptide-Based Oligomers6.2.6 AApeptides; 6.2.6.1 α-AApeptides; 6.2.6.2 γ-AApeptides; 6.3 Discussion; Acknowledgments; References; Chapter 7 Synthetic Biology and Therapies for Infectious Diseases; 7.1 Current Challenges in the Treatment of Infectious Diseases; 7.2 Introduction to Synthetic Biology; 7.3 Vaccinology; 7.3.1 Genetic Engineering and Vaccine Development; 7.3.2 Rational Antigen Design Through Reverse Vaccinology; 7.4 Bacteriophages: A Re-emerging Solution?; 7.4.1 A Brief History of Bacteriophages7.4.2 Addressing the Problem of the Restricted Host Range of PhagesBy integrating knowledge from pharmacology, microbiology, molecular medicine, and engineering, researchers from Europe, the U.S. and Asia cover a broad spectrum of current and potential antimicrobial medications and treatments. The result is a comprehensive survey ranging from small-molecule antibiotics to antimicrobial peptides and their engineered mimetics, from enzymes to nucleic acid therapeutics, from metallic nanoparticles to photo- and sonosensitizers and to phage therapy. In each case, the therapeutic approaches are compared in terms of their mechanisms, likelihood to induce resistanceDisinfection and disinfectantsAnti-infective agentsSterilizationDisinfection and disinfectants.Anti-infective agents.Sterilization.614.48Phoenix David A.Harris FrederickDennison Sarah R.Ahmed WaqarMiAaPQMiAaPQMiAaPQBOOK9910817868703321Novel antimicrobial agents and strategies3965022UNINA